2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 52

Interferon-Alpha Protects Against Pain and Joint Damages in Experimental Arthritis and Is Associated with Expansion of Highly Suppressive Regulatory T Lymphocytes in Protected Mice and in Tocilizumab-Treated Rheumatoid Arthritis Patients
Abstract Number: 2685

Interferon-Inducible Gene Expression Kit As a Potential Diagnostic Test for Anifrolumab: Analytical Validation for Use in Clinical Trials
Abstract Number: 613

Interim Analysis of Baseline Characteristics and Preferences of Administration Route of Rheumatoid Arthritis Patients Who Are Bio-Naïve or Switched between Advanced RA Treatments; A Multicenter, Prospective, Observational Study
Abstract Number: 2287

Interim Results of an Open-Label Study Assessing Efficacy and Safety of Adrenocorticotropic Hormone Gel for Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
Abstract Number: 720

Interkeukin-6 Level in Cerebrospinal Fluid As a Biomarker for Systemic Lupus Erythematosus Patients with Longitudinally Extensive Transverse Myelitis like Neuromyelitis Optica Spectrum Disease
Abstract Number: 842

Interleukin 17 Receptor D (IL-17RD) Is Regulated By Pro-Inflammatory Cytokines and Plays a Role in the Development of Collagen-Induced Arthritis
Abstract Number: 404

Interleukin 17A– a Translational Target to Treat Supraspinatus Tendinopathy
Abstract Number: 445

Interleukin-1β Inhibition with Canakinumab Associates with Reduced Rates of Total Hip and Knee Replacement (THR/TKR) and Osteoarthritis (OA) Symptoms: Exploratory Results from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
Abstract Number: 2000

Interleukin-1β, Oxidative Stress and Basic Calcium Phosphate Crystals Induce Osteoarthritis-like Changes in Chondrocyte Phenotype By Altering the Expression of PERIOD2, a Core Component of the Chondrocyte Circadian Clock
Abstract Number: 2776

Interleukin-6 Expression in Inflamed and Non-Inflamed Temporal Arteries from Patients with Giant Cell Arteritis
Abstract Number: 868

International Multi-Reader Validation of the Outcome Measures in Rheumatology Hip MRI Scoring System (OMERACT HIMRISS) for Bone Marrow Lesions in Osteoarthritis
Abstract Number: 1662

Interplay Among Inflammation, Adipokines and Endothelial Dysfunction in Patients with Psoriatic Arthritis. Relationship with Cardiovascular and Metabolic Comorbidities. Modulation By Apremilast
Abstract Number: 255

Interpretation of Proverbs Compared with the Mental Clutter Scale in Fibromyalgia Patients Demonstrates Intact Intellectual Ability Despite the Symptoms of Fibrofog
Abstract Number: 632

Interpretation of Symptoms Should Take into Account Gender in Psoriatic Arthritis: An Analysis of 451 Patients
Abstract Number: 1751

Interstitial Lung Disease during ANCA-Associated Vasculitis: A Poor-Prognosis Factor

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].